These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 27192055)

  • 1. Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.
    Graff JN; Higano CS; Hahn NM; Taylor MH; Zhang B; Zhou X; Venkatakrishnan K; Leonard EJ; Sarantopoulos J
    Cancer; 2016 Aug; 122(16):2524-33. PubMed ID: 27192055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.
    Venkatakrishnan K; Kim TM; Lin CC; Thye LS; Chng WJ; Ma B; Chen MH; Zhou X; Liu H; Kelly V; Kim WS
    Invest New Drugs; 2015 Aug; 33(4):942-53. PubMed ID: 26084989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.
    Kelly KR; Friedberg JW; Park SI; McDonagh K; Hayslip J; Persky D; Ruan J; Puvvada S; Rosen P; Iyer SP; Stefanovic A; Bernstein SH; Weitman S; Karnad A; Monohan G; VanderWalde A; Mena R; Schmelz M; Spier C; Groshen S; Venkatakrishnan K; Zhou X; Sheldon-Waniga E; Leonard EJ; Mahadevan D
    Clin Cancer Res; 2018 Dec; 24(24):6150-6159. PubMed ID: 30082475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations.
    Dees EC; Cohen RB; von Mehren M; Stinchcombe TE; Liu H; Venkatakrishnan K; Manfredi M; Fingert H; Burris HA; Infante JR
    Clin Cancer Res; 2012 Sep; 18(17):4775-84. PubMed ID: 22767670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.
    Falchook G; Kurzrock R; Gouw L; Hong D; McGregor KA; Zhou X; Shi H; Fingert H; Sharma S
    Invest New Drugs; 2014 Dec; 32(6):1181-7. PubMed ID: 24879333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
    DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
    J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
    Falchook GS; Zhou X; Venkatakrishnan K; Kurzrock R; Mahalingam D; Goldman JW; Jung J; Ullmann CD; Milch C; Rosen LS; Sarantopoulos J
    Drugs R D; 2016 Mar; 16(1):45-52. PubMed ID: 26689566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors.
    Shah HA; Fischer JH; Venepalli NK; Danciu OC; Christian S; Russell MJ; Liu LC; Zacny JP; Dudek AZ
    Am J Clin Oncol; 2019 May; 42(5):413-420. PubMed ID: 30973373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.
    Lin J; Patel SA; Sama AR; Hoffman-Censits JH; Kennedy B; Kilpatrick D; Ye Z; Yang H; Mu Z; Leiby B; Lewis N; Cristofanilli M; Kelly WK
    Oncologist; 2016 Nov; 21(11):1296-1297e. PubMed ID: 28178640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
    Falchook GS; Venkatakrishnan K; Sarantopoulos J; Kurzrock R; Mita AC; Fu S; Mita MM; Zhou X; Jung JA; Ullmann CD; Milch C; Rosen LS
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):563-72. PubMed ID: 26073352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors.
    Semrad TJ; Kim EJ; Gong IY; Li T; Christensen S; Arora M; Riess JW; Gandara DR; Kelly K
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):335-341. PubMed ID: 33993383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships.
    Venkatakrishnan K; Zhou X; Ecsedy J; Mould DR; Liu H; Danaee H; Fingert H; Kleinfield R; Milton A
    J Clin Pharmacol; 2015 Mar; 55(3):336-47. PubMed ID: 25302940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.
    Cervantes A; Elez E; Roda D; Ecsedy J; Macarulla T; Venkatakrishnan K; Roselló S; Andreu J; Jung J; Sanchis-Garcia JM; Piera A; Blasco I; Maños L; Pérez-Fidalgo JA; Fingert H; Baselga J; Tabernero J
    Clin Cancer Res; 2012 Sep; 18(17):4764-74. PubMed ID: 22753585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib).
    Huck JJ; Zhang M; Mettetal J; Chakravarty A; Venkatakrishnan K; Zhou X; Kleinfield R; Hyer ML; Kannan K; Shinde V; Dorner A; Manfredi MG; Shyu WC; Ecsedy JA
    Mol Cancer Ther; 2014 Sep; 13(9):2170-83. PubMed ID: 24980948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
    Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia.
    Zhou X; Mould DR; Takubo T; Sheldon-Waniga E; Huebner D; Milton A; Venkatakrishnan K
    Br J Clin Pharmacol; 2018 Jan; 84(1):35-51. PubMed ID: 28891222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.
    Amin M; Minton SE; LoRusso PM; Krishnamurthi SS; Pickett CA; Lunceford J; Hille D; Mauro D; Stein MN; Wang-Gillam A; Trull L; Lockhart AC
    Invest New Drugs; 2016 Feb; 34(1):84-95. PubMed ID: 26620496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.
    Fathi AT; Wander SA; Blonquist TM; Brunner AM; Amrein PC; Supko J; Hermance NM; Manning AL; Sadrzadeh H; Ballen KK; Attar EC; Graubert TA; Hobbs G; Joseph C; Perry AM; Burke M; Silver R; Foster J; Bergeron M; Ramos AY; Som TT; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Chen YB
    Haematologica; 2017 Apr; 102(4):719-727. PubMed ID: 28034990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).
    Mossé YP; Fox E; Teachey DT; Reid JM; Safgren SL; Carol H; Lock RB; Houghton PJ; Smith MA; Hall D; Barkauskas DA; Krailo M; Voss SD; Berg SL; Blaney SM; Weigel BJ
    Clin Cancer Res; 2019 Jun; 25(11):3229-3238. PubMed ID: 30777875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.
    Sehdev V; Katsha A; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W
    Cancer; 2013 Feb; 119(4):904-14. PubMed ID: 22972611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.